Inspira Announces 97.3% Accuracy Results for HYLA™ Blood Sensor, Advancing Toward FDA Submission for Clearance
IINN(NASDAQ:IINN) RA'ANANA, Israel, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced pivotal results for its HYLA blood sensor, achieving 97.35% accuracy in its latest performance testing phase that will support its upcoming U.S. Food and Drug Administration (“FDA”) submission. These results represent a significant advancement from the initial data obtained in a clinical study, as announced on March 4, 2025.
Inspira Receives U.S. Patent Approval for the ART500 Core Technology, Key Patent Positions the Company to Dominate $20 Billion Estimated Market
IINNRA'ANANA, Israel, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, has received U.S. Patent approval for low flow rates extracorporeal oxygenation system and methods of use. This patent represents the core technology of the ART500 device, a key asset in the Company’s strategy to penetrate the $20 billion estimated market for advanced respiratory support. This innovation has 16 claims found to be novel.
Inspira Secures $27 Million Government Binding Purchase Order for ART100 Systems with Full Payment in 2025
IINNRA'ANANA, Israel, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced that a national ministry of health in Africa (the “Ministry of Health”) has placed a $27 million binding purchase order for Inspira’s FDA-cleared ART100 systems. The purchase order, secured through Inspira’s exclusive distribution partner, dedicated solely to the commercialization of Inspira’s products, initiates an immediate nationwide deployment program.
Inspira Clarifies Routine Nature of Registration Statement on Form F-3 Filing Performed Every Three Years
IINNRA'ANANA, Israel, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced that it has filed a shelf registration statement on Form F-3 (File No. 333-289324) with the U.S. Securities and Exchange Commission on August 6, 2025, as part of a routine shelf renewal process conducted every three years. This updated filing replaces the Company’s previous shelf registration statement, which is set to expire on August 18, 2025.
Inspira Technologies Sees Surge In Commercial Interest Following FDA-Cleared ART100 System Integration At Tier-1 U.S. Hospitals
IINNInspira Technologies Scales-Up Production Capabilities For FDA-Cleared INSPIRA ART100 System In Response To Expected Demand From European Governmental Authority
IINNLitchfield Hills Initiates Coverage On Inspira Technologies Oxy with Buy Rating, Announces Price Target of $2
IINNInspira Technologies Announces Strategic Shift To Accelerate Commercialization Of FDA-Cleared INSPIRA ART100 System, While Maintaining Development, Regulatory Pathways Of Its Portfolio
IINNInspira Announces Joe Hayon, Co-Founder And President Will Be Stepping Down From His Operational Role As President of Inspira And Will Continue To Serve As An Active Board Member
IINNInspira Technologies' FDA-Approved INSPIRA ART100 To Undergo Clinical Validation By Israel's Largest Healthcare Provider For Use In Organ Transplants
IINNInspira Technologies Oxy Achieves Over 99% Gas Exchange Target In-Vivo Testing Of Next-Generation Vortx Technology
IINNInspira Technologies Received Payment From Glo-Med Networks For Delivery Of INSPIRA ART100 Systems; Revenue In Range Of ow Hundreds Of Thousands Of Dollars Relates To Delivery Of INSPIRA ART100 Systems
IINNInspira Technologies Completes Treatment Of First Patient with INSPIRA ART100 At Westchester Medical Center
IINNInspira Technologies' Life-Support System To Be Showcased At AmSECT International Conference March 19-23, 2025
IINNInspira Technologies Expects To Receive A Prepayment From Its U.S. Distributor For INSPIRA ART100 Systems For Planned Deployment In Select Hospitals
IINNInspira Receives Written Notice That It Was Not In Compliance With Nasdaq Listing Rule
IINNInspira Technologies Reports FY24 Financial Results; As Of December 31, 2024, The Company Had Cash, Cash Equivalents And Deposits Of $5,779,000
IINNCORRECTION: Inspira Technologies Reported Clinical Outcomes For HYLA Blood Sensor On March 4, 2025
IINNInspira Technologies Reported Clinical Outcomes For HYLA Blood Sensor
IINNInspira Technologies Announces Results From Clinical Study Of Its HYLA Blood Sensor Showing 96% Accuracy
IINNEXCLUSIVE: Inspira Technologies Unveils Modular Configuration For VORTX Blood Oxygenation Delivery Technology
IINNInspira Technologies unveils modular VORTX system, targeting enhanced oxygen delivery and reduced risks for ICU patients with respiratory failure.
EXCLUSIVE: Inspira Technologies Tell Benzinga Co. Unveils Modular Configuration For VORTX Blood Oxygenation Delivery Technology
IINNInspira Technologies Launches Preparation For Potential Production Ramp-up Of Its INSPIRA ART100 Device In Strategic Readiness Amid Recent Outbreak Of Human Metapneumovirus In China
IINN